TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 10, 2020

Empagliflozin helps lower diastolic pulmonary artery pressure in patients who have heart failure with either reduced ejection fraction or preserved ejection fraction, regardless of diabetes status, according to results of the EMBRACE HF trial. Pressures were monitored remotely in patients who had an existing implanted device.

“We saw an early, significant effect on lowering pulmonary artery diastolic pressure that became apparent within a few weeks and continued to widen over time,” said Mikhail Kosiborod, MD, Saint Luke’s Mid America Heart Institute, Kansas City, MO.

Pulmonary artery pressure is a strong predictor of clinical status, hospitalizations and death that had not previously been examined with sodium-glucose cotransporter 2 (SGLT2) inhibitors in this context, he added.

Read the full article on TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Related Content

Healio: Two studies provide further positive outcomes for empagliflozin in HF
Dr. Mikhail Kosiborod explains the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with HF and higher diastolic pulmonary artery pressure.
research image with doctor and stethoscope, medication and blood platelets
Saint Luke’s leads first of its kind trial to help patients with heart failure – DEFINE-HF
DEFINE-HF was not only the first multi-center randomized placebo-controlled clinical trial that Saint Luke’s developed, coordinated, and implemented in its entirety, but the first significant effort to look at what effect dapagliflozin, a drug initially created for the treatment of diabetes, was going to have in patients who also have heart failure.